N
PACB icon

Nuveen’s Pacific Biosciences PACB Stock Holding History

Nuveen’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-185,600
Closed -$6K – 3444
2021
Q2 		$6K Buy
+185,600
New +$5.4M ﹤0.01% 3300
2021
Q1 		– Sell
-102,200
Closed -$3K – 3399
2020
Q4 		$3K Buy
+102,200
New +$1.74M ﹤0.01% 3294

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nuveen's PACB Position: Q1 2026 in Review

Nuveen increased its Pacific Biosciences (PACB) stake by 248% in Q1 2026, buying an estimated $3.76M and bringing the position to 2,950,929 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

Nuveen first reported a position in PACB in Q2 2019 and has held it in 28 quarters since. The position peaked at $44.7M in Q2 2021. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Nuveen held 2,950,929 shares of Pacific Biosciences worth $3.9M as of Q1 2026.
  • Nuveen bought 2,102,710 Pacific Biosciences shares in Q1 2026, an estimated $3.76M.
  • Pacific Biosciences made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1984 holding.
  • Nuveen first reported a position in Pacific Biosciences in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Pacific Biosciences position peaked at $44.7M in Q2 2021.
  • 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.